{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:40:27Z","timestamp":1792521627799,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"DOI":"10.1007\/s10147-026-03204-x","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:02:37Z","timestamp":1792519357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of neoadjuvant S-1 and oxaliplatin therapy for gastric cancer in the elderly: combined phase II trials of KSCC1601 and KSCC1801"],"prefix":"10.1007","author":[{"given":"Keiichiro","family":"Ryujin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Natsugoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Nambara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakanoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Iwatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Yoshizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-9366","authenticated-orcid":false,"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"3204_CR1","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, Zhao HP, Yu Y et al (2023) Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol 29:2452\u20132468","journal-title":"World J Gastroenterol"},{"key":"3204_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19104-6","volume":"24","author":"JL Lin","year":"2024","unstructured":"Lin JL, Lin JX, Lin GT et al (2024) Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035. BMC Public Health 24:1763","journal-title":"BMC Public Health"},{"key":"3204_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000518483","volume":"103","author":"M Sekiguchi","year":"2022","unstructured":"Sekiguchi M, Oda I, Matsuda T et al (2022) Epidemiological trends and future perspectives of gastric cancer in Eastern Asia. Digestion 103:22\u201328","journal-title":"Digestion"},{"key":"3204_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/ags3.12835","volume":"8","author":"T Higashi","year":"2024","unstructured":"Higashi T, Kurokawa Y (2024) Incidence, mortality, survival, and treatment statistics of cancers in digestive organs: Japanese cancer statistics 2024. Ann Gastroenterol Surg 8:958\u2013965","journal-title":"Ann Gastroenterol Surg"},{"key":"3204_CR5","unstructured":"Cancer Statistics in Japan (1958\u20132022). Available at: https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html. Accessed 29 September 2025"},{"key":"3204_CR6","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387\u20134393","journal-title":"J Clin Oncol"},{"key":"3204_CR7","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 15:1389\u20131396","journal-title":"Lancet Oncol"},{"key":"3204_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11\u201320","journal-title":"N Engl J Med"},{"key":"3204_CR9","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393:1948\u20131957","journal-title":"Lancet"},{"key":"3204_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA et al (2025) Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med 393:217\u2013230","journal-title":"N Engl J Med"},{"key":"3204_CR11","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1097\/MS9.0000000000001817","volume":"86","author":"ZK Tan","year":"2024","unstructured":"Tan ZK, Tang WZ, Jia K et al (2024) Relation between frailty and adverse outcomes in elderly patients with gastric cancer: a scoping review. Ann Med Surg (Lond) 86:1590\u20131600","journal-title":"Ann Med Surg (Lond)"},{"key":"3204_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s10120-021-01265-7","volume":"25","author":"DU Lee","year":"2022","unstructured":"Lee DU, Kwon J, Han J et al (2022) The clinical impact of frailty on the postoperative outcomes of patients undergoing gastrectomy for gastric cancer: a propensity-score matched database study. Gastric Cancer 25:450\u2013458","journal-title":"Gastric Cancer"},{"key":"3204_CR13","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","volume":"41","author":"W Dale","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR et al (2023) Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol 41:4293\u20134312","journal-title":"J Clin Oncol"},{"key":"3204_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10120-015-0549-1","volume":"19","author":"H Bando","year":"2016","unstructured":"Bando H, Yamada Y, Tanabe S et al (2016) Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer 19:919\u2013926","journal-title":"Gastric Cancer"},{"key":"3204_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000130","volume":"2","author":"H Satake","year":"2017","unstructured":"Satake H, Miki A, Kondo M et al (2017) Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI). ESMO Open 2:e000130","journal-title":"ESMO Open"},{"key":"3204_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s12032-021-01549-z","volume":"38","author":"A Serizawa","year":"2021","unstructured":"Serizawa A, Kuramochi H, Taniguchi K et al (2021) Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer clinical T4 or N2\u20133. Med Oncol 38:98","journal-title":"Med Oncol"},{"key":"3204_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102528","volume":"101","author":"F Zhang","year":"2024","unstructured":"Zhang F, Yan Y, Ge C (2024) Frailty as a predictor of adverse outcomes in patients with gastric cancer: a systematic review and meta-analysis of 75,357 patients. Ageing Res Rev 101:102528","journal-title":"Ageing Res Rev"},{"key":"3204_CR18","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR et al (2018) Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol 36:2326\u20132347","journal-title":"J Clin Oncol"},{"key":"3204_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10120-021-01218-0","volume":"25","author":"M Iwatsuki","year":"2022","unstructured":"Iwatsuki M, Orita H, Kobayashi K et al (2022) Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. Gastric Cancer 25:180\u2013187","journal-title":"Gastric Cancer"},{"key":"3204_CR20","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s10147-023-02373-3","volume":"28","author":"M Ota","year":"2023","unstructured":"Ota M, Saeki H, Uehara H et al (2023) Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients. Int J Clin Oncol 28:1166\u20131175","journal-title":"Int J Clin Oncol"},{"key":"3204_CR21","unstructured":"(2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20:1-19"},{"key":"3204_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205\u2013213","journal-title":"Ann Surg"},{"key":"3204_CR23","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer A (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101\u2013112","DOI":"10.1007\/s10120-011-0041-5"},{"key":"3204_CR24","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41416-021-01367-0","volume":"124","author":"CM Lund","year":"2021","unstructured":"Lund CM, Vistisen KK, Olsen AP et al (2021) The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO). Br J Cancer 124:1949\u20131958","journal-title":"Br J Cancer"},{"key":"3204_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1159\/000539774","volume":"47","author":"B Rodriguez-Arroyo","year":"2024","unstructured":"Rodriguez-Arroyo B, Caraballo P, Pineda-Isaza A et al (2024) Geriatric assessment scale for optimal management of gastric cancer in older adults who underwent gastrectomy: a systematic review. Oncol Res Treat 47:420\u2013429","journal-title":"Oncol Res Treat"},{"key":"3204_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215\u2013221","journal-title":"Lancet Oncol"},{"key":"3204_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.7150\/jca.13248","volume":"7","author":"HS Kim","year":"2016","unstructured":"Kim HS, Kim JH, Kim JW et al (2016) Chemotherapy in elderly patients with gastric cancer. J Cancer 7:88\u201394","journal-title":"J Cancer"},{"issue":"2","key":"3204_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10147-020-01803-w","volume":"26","author":"T Kashiwada","year":"2021","unstructured":"Kashiwada T, Shinozaki K, Ueno S et al (2021) Safety and efficacy of S-1 plus oxaliplatin 130\u00a0mg\/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: a phase II trial (KSCC1501A). Int J Clin Oncol 26(2):345\u2013354","journal-title":"Int J Clin Oncol"},{"key":"3204_CR29","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s10120-023-01376-3","volume":"26","author":"K Sakurai","year":"2023","unstructured":"Sakurai K, Kubo N, Hasegawa T et al (2023) Risk factors of \u201closs of independence\u201d in elderly patients who received gastrectomy for gastric cancer. Gastric Cancer 26:638\u2013647","journal-title":"Gastric Cancer"},{"key":"3204_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153768","author":"WL Chan","year":"2023","unstructured":"Chan WL, Liu X, Wong CK et al (2023) Adjuvant chemotherapy in older patients with gastric cancer: a population-based cohort study. Cancers. https:\/\/doi.org\/10.3390\/cancers15153768","journal-title":"Cancers"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03204-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03204-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03204-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:02:38Z","timestamp":1792519358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03204-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":30,"alternative-id":["3204"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03204-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EO reports research funding from Guardant Health, Inc. and reports honoraria from Chugai Pharmaceutical, Eli Lilly, Takeda Pharmaceutical, Bristol and Ono Pharm. The other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a prespecified ancillary correlative analysis embedded in the multi center prospective phase II KSCC1601(jRCTs071180064) and KSCC1801(jRCTs071180001) trials conducted in Japan. Both KSCC KSCC1601 and KSCC1801 were performed in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and its later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}